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Abstract
Introduction: We report an unexpected presentation of metastatic renal cell carcinoma (RCC) to the ciliary body
and an interesting response to proton beam radiotherapy.
Case presentation: We encountered a case of angle-closure glaucoma as the initial presentation of ocular
metastasis to the ciliary body in a 65-year-old Caucasian man who had undergone right radical nephrectomy for
RCC 15 years earlier. He underwent YAG (yttrium aluminium garnet) laser peripheral iridotomy while further
metastatic workup took place. His condition was eventually diagnosed as stage IV metastatic RCC of the clear cell
type and involved multiple sites, including the ciliary body, brain, lungs, liver, and pancreas. The progression of RCC
metastasis to the ciliary body was studied for 16 months. The ciliary body mass continued to grow despite
systemic treatment with temsirolimus and interleukin-2 and intravitreal injections of bevacizumab. The tumor size
peaked at 6.11 × 6.06 mm before the start of proton therapy, which reduced the tumor size to 5.07 × 4.39 mm.
Conclusions: RCC can produce metastases involving unusual sites many years after resection of the primary tumor.
Proton therapy was found to be effective in treating RCC metastasis to the ciliary body in settings in which other
treatment modalities failed.
Introduction
Renal cell carcinoma (RCC) accounts for approximately
85% of primary renal neoplasms and represents approxi-
mately 3% of all adult malignancy [1]. The most com-
mon sites of metastasis are the lung (50%) and the bone
(33%), but RCC has been documented to metastasize to
every organ and site in the body by hematogenous
spread. The interval between RCC systemic and ocular
presentations varies and may become so prolonged as to
obscure the relationship between the ocular metastasis
and the primary RCC tumor [2]. In a pathologic survey,
Ferry and Font [3] demonstrated that only seven out of
196 cases of ocular metastatic carcinoma originated
from RCCs. Ocular metastases from RCC are most
likely to involve the iris [4], ciliary body [5], and chor-
oids, although eyelid and orbital metastases have been
described [6].
We report a rare case of angle-closure glaucoma sec-
ondary to ciliary body metastasis in a patient who
underwent radical nephrectomy for RCC 15 years ear-
lier. Also, we review the different treatment modalities
we used to treat the ocular metastasis.
Case presentation
A 65-year-old Caucasian man presented to our emer-
gency department and complained of sudden-onset
blurry vision and pain in his right eye. He reported asso-
ciated nausea and a right-sided headache. His medical
history was significant for RCC, for which he had under-
gone right radical nephrectomy 15 years earlier. After
the initial nephrectomy, he had completed 10 years of
surveillance, after which he was thought to be disease-
free.
At presentation, his best corrected visual acuities were
20/50 in his right eye (oculus dexter, or OD) and 20/20
in his left eye (oculus sinister, or OS). The intraocular
pressures by applanation tonometry were 50 mm Hg
OD and 14 mm Hg OS. The results of a left eye exam
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were unremarkable. A slit-lamp exam of his right eye
demonstrated a red mass that was located in the super-
ior nasal aspect of his iris at one to three o’clock and
that was associated with dilated episcleral feeder vessels
(Figure 1a). A gonioscopy showed a closed angle with
the iris bowing forward to the superior nasal sector of
the anterior chamber angle. A high-frequency immer-
sion B-scan ultrasonography of his right eye revealed a
ciliary body mass, which was pushing his iris forward
toward his cornea (Figure 2a). An iris angiography of his
right eye showed an area of hyperfluorescence over the
area of his tumor (Figure 1b). A fundus examination of
his right eye showed no evidence of choroidal or retinal
involvement.
His condition was diagnosed as acute angle-closure
glaucoma (AACG) secondary to a ciliary body mass in
his right eye. He was started on timolol, acetazolmide,
and latanoprost followed by a YAG (yttrium aluminium
garnet) laser peripheral iridotomy to lower the intraocu-
lar pressure.
The results of a further metastatic workup were con-
sistent with a stage IV RCC that was of the clear cell
type (Figure 3) and that involved the ciliary body, brain,
lungs, liver, and pancreas.
The ciliary body mass continued to grow despite sys-
temic treatment with temsirolimus (mammalian target of
rapamycin inhibitor) [7] and interleukin-2 (IL-2) (Figure






Figure 1 (a) Slit-lamp exam (SLE) photograph of the right eye at presentation shows a red mass in the superior nasal aspect of the
iris at one to three o’clock. (b) Iris angiography of the right eye shows an area of hyperfluorescence over the area of the tumor. (c) SLE
photograph of the right eye 10 months later (status after systemic treatment with temsirolimus and interleukin-2 and intravitreal injections of
bevacizumab) shows that the red mass had grown. (d) SLE photograph delineates the mass-lens adhesions prior to proton beam radiotherapy.
(e) SLE photograph of the right eye after proton radiotherapy shows a significant decrease in the size of the mass.
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two intravitreal injections of bevacizumab failed to slow
the growth of the mass, and the tumor size peaked at 6.11
× 6.06 mm (Figure 2a). Some adhesions have developed
between the mass and the lens (Figure 1d).
Lastly, proton radiotherapy was administered. Tanta-
lum clips were placed to outline the posterior margin of
the tumor. Our patient received a total of 30 cobalt gray
equivalents (CGE) in three fractions given over the
course of six calendar days. As a result, the tumor size
decreased to 5.07 × 4.39 mm (Figures 1e and 2b). Later,
our patient underwent an uneventful cataract extraction
and an intraocular lens placement in his right eye. His
current visual acuity in his right eye is 20/40.
Discussion
The mechanism of ocular spread in RCC is presumed to
take place through venous diffusion within the small
chroidal vessels, and neoplastic cells travel as emboli [8].
Simultaneous bilateral iris metastases from RCC were
described by Wizinski and colleagues [4]. Two cases of
spontaneous disappearance of choroidal metastasis from
RCC after nephrectomy have been described [9,10].
Shome and colleagues [11] reported a case of iris metas-
tasis from RCC 14 months after a right nephrectomy.
Mancini and colleagues [8] reported a case of left ciliary
body metastasis in a 42-year-old man who had under-
gone a left radical nephrectomy for conventional RCC
six years earlier. Our patient is unusual because, before
he presented with AACG, he was thought to be disease-
free for 15 years after nephrectomy but he was even-
tually discovered to have widespread RCC metastasis.
Although the extraocular metastasis showed a reason-
able response to systemic temsirolimus and IL-2, the
ciliary body metastasis failed to do so. One theory may
question the bioavailability of these systemic agents in
the ciliary body circulation system.
Primary RCC produces angiogenic growth factors
(such as basic fibroblastic growth factor and vascular
endothelial growth factor), which are responsible for
tumor growth, proliferation, metastases, and survival
through high serum levels [12]. Unfortunately, our
a b
Figure 2 (a) High-frequency immersion B-scan ultrasonography of the right eye reveals the ciliary body mass at a peak size of 6.11 ×
6.06 mm. (b) B-scan ultrasonography after proton radiotherapy reveals the regression of the ciliary body mass size to 5.07 × 4.39 mm.
Figure 3 Histopathologic image of optically clear cytoplasm,
sharply outlined cell membranes, round to irregular nuclei,
and prominent nucleoli. Pathology findings are consistent with
clear cell carcinoma, Fuhrman grade III (renal cell carcinoma
metastasis).
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patient’s tumor continued to grow despite intravitreal
injections of bevacizumab (anti-vascular endothelial
growth factor).
The prognosis of metastatic RCC is generally poor;
median survival is 10 months and five-year survival is
less than 5% [13,14]. Our patient has survived for 16
months with an extraocular response to the systemic
temsirolimus and IL-2. His affected eye maintained
visual acuity and the ciliary body mass regressed in
response to the proton radiotherapy followed by suc-
cessful cataract surgery.
Several urologists advocated RCC surveillance for at
least 10 years after the initial nephrectomy. Others con-
cluded that follow-up for life is reasonable [15-20]. Our
case report would emphasize such extended surveillance
as long as it is individualized and cost-conscious.
Conclusions
We present an interventional case report in which the
progression of RCC metastasis to the ciliary body was
studied for 16 months. The response to different treat-
ment modalities was investigated. The ciliary body mass
continued to grow despite systemic treatment with tem-
sirolimus and IL-2 and intravitreal injections of bevaci-
zumab. The tumor size peaked at 6.11 × 6.06 mm
before the start of proton therapy, which reduced the
tumor size to 5.07 × 4.39 mm. To the best of our
knowledge, this is the first case report of a ciliary body
metastasis from RCC that responded to proton radio-
therapy after other treatment modalities had failed.
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